Truist downgraded PRA Health Sciences from Buy to Hold and set a new price target of $175.00 from $196.00 previously

Credit Suisse reiterated coverage of PRA Health Sciences with a rating of Outperform and set a new price target of $169.00 from $159.00 previously

Baird downgraded PRA Health Sciences from Outperform to Neutral and set a new price target of $165.00

KeyCorp resumed coverage of PRA Health Sciences with a rating of Sector Weight

KeyBanc downgraded PRA Health Sciences from Overweight to Sector Weight

Jefferies Financial Group downgraded PRA Health Sciences from Buy to Hold

Strengthening Board of Directors with Expertise in Innovative Product Launches NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Ms. Jiong Ma, PhD to its Board of Directors. Ms. Ma is Senior Board executive with over 25 years of experience in investing, building, scaling of companies with focus on innovative product launches in

4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

4 - PRA Health Sciences, Inc. (0001613859) (Issuer)

4/A - PRA Health Sciences, Inc. (0001613859) (Issuer)

SC 13G - PRA Health Sciences, Inc. (0001613859) (Subject)

SC 13G/A - PRA Health Sciences, Inc. (0001613859) (Subject)

SC 13G/A - PRA Health Sciences, Inc. (0001613859) (Subject)

SC 13G - PRA Health Sciences, Inc. (0001613859) (Subject)

SC 13G/A - PRA Health Sciences, Inc. (0001613859) (Subject)

SC 13G - PRA Health Sciences, Inc. (0001613859) (Subject)

SC 13G/A - PRA Health Sciences, Inc. (0001613859) (Subject)

SC 13G/A - PRA Health Sciences, Inc. (0001613859) (Subject)

Believes Incumbent Board's Approval and Ongoing Pursuit of Reckless and Dilutive Proposed Merger with Akoya Biosciences Demonstrates Urgent Need for Refreshment Nominees Would Bring Deep Healthcare and Financial Experience Necessary to Properly Oversee a Standalone Quanterix, Prevent Further Capital Misallocation and Improve Shareholder Value Kent Lake Urges Shareholders to Vote Against Merger with Akoya to Protect the Future Value of Their Investment Kent Lake PR LLC ("Kent Lake"), a holder of 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), announced today it has nominated three highly qualified, independent candidates for e

NEW YORK, June 28, 2021 /PRNewswire/ -- DT Midstream Inc. (NYSE:DTM) will replace PRA Health Sciences Inc. (NASD: PRAH) in the S&P MidCap 400 effective prior to the open on Friday, July 2. ICON plc (NASD: ICLR) is acquiring PRA Health Sciences in a deal expected to be completed soon pending final closing conditions. S&P 500 constituent DTE Energy Co. (NYSE:DTE) is spinning off DT Midstream in a transaction expected to be effective prior to the open on Thursday, July 1. Post spin-off, DTE Energy will remain in the S&P 500.   Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker

Through this strategic partnership, the network aims to reach more than 25,000 physicians and 40 million patients, accelerating trial recruitment and enrollment efforts and expanding patients' access to clinical research Veradigm®, a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ:MDRX), and PRA Health Sciences, Inc. (NASDAQ:PRAH), one of the world's leading global contract research organizations, announced today the creation of the industry's leading electronic healthcare records-based clinical research network that reaches more than 25,000 physicians and 40 million patients across the United States. This press re

Veranex today announced the formation of the first concept-to-commercialization global service provider dedicated to the medtech industry. Formed in partnership with global growth investor Summit Partners, the Veranex platform is designed to provide the global medical technology industry with access to real-time integrated strategy across the product life cycle. As the first phase in building this global entity, Veranex has acquired three complementary solution providers: Ximedica, Quartesian, and Boston Healthcare Associates. By bringing these companies together, Veranex combines the industry's key pillars of design and engineering, regulatory, clinical, and market access into a single-sou

Strengthening Board of Directors with Expertise in Innovative Product Launches NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Ms. Jiong Ma, PhD to its Board of Directors. Ms. Ma is Senior Board executive with over 25 years of experience in investing, building, scaling of companies with focus on innovative product launches in

RALEIGH, N.C., May 13, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) announced today an innovative tokenization solution using Synoma®, PRA's proprietary technology that allows for the generation of enhanced evidence for drug development. PRA's solution makes it possible to connect clinical trial data and secondary data sets with privacy at the forefront. Today, three large pharmaceutical companies, along with several other pharmaceutical and biotech companies of all sizes, are using Synoma to link data and conduct analyses across their drug development portfolios. "Data of all types is widely available from dozens of sources. The missing link, however, is the ability t

Net new business of $797.2 million; representing growth of 31.8%; Net book-to-bill of 1.24 excluding reimbursement revenueNet new business of $1,154.4 million; representing growth of 20.8%; Net book-to-bill of 1.33 including reimbursement revenue$933.8 million of total revenue; representing growth of 19.1% at actual foreign exchange rates and 17.6% on a constant currency basisGAAP net income per diluted share of $0.86; GAAP net income of $56.9 million Adjusted net income per diluted share was $1.35, representing growth of 28.6%; Adjusted net income of $89.6 million, representing growth of 33.0% RALEIGH, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. ("PRA," "we," "us"

RALEIGH, N.C., April 21, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ:PRAH) announced today the expansion of its pharmacovigilance solution to offer full post-marketing services for authorized COVID-19 vaccines and therapeutics, including post-authorization safety studies (PASS) delivered by Real World Solutions. With more than 25 years of experience executing comprehensive pharmacovigilance and patient safety services in all key therapeutic areas including infectious diseases, PRA can work closely with drug developers and manufacturers in ensuring long-term safety and efficacy of COVID-19 vaccines and treatments. With thousands of COVID-19 vaccines, therapies, and new and complex

RALEIGH, N.C. and BALTIMORE, April 13, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ:PRAH) and the Maryland State Medical Society (MedChi) announced today that Care Innovations, a PRA Health Sciences company, was selected by MedChi to be a preferred provider of remote patient monitoring, telehealth, and digital health services for its network of 22,000+ licensed physicians who practice across 50+ medical specialties. Maryland physicians now have a trusted provider to quickly deploy a secure and privacy-compliant system for maintaining patients' care remotely, including routine visits and chronic disease management. "This is the time to embrace RPM to manage patient care," said Gene

RALEIGH, N.C. , April 07, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today that Merck KGaA, Darmstadt, Germany, known in the United States as EMD Serono, selected PRA’s remote patient monitoring platform to work in combination with its human growth hormone (HGH) treatment system. Under this agreement, PRA’s remote patient monitoring platform backs Merck KGaA, Darmstadt, Germany’s HGH treatment system, including growlinkTM, a mobile app for patients prescribed with HGH treatment, and easypod® Connect, a secure platform for healthcare professionals (HCP) in the field of endocrinology to monitor patients’ adherence, review injection history, and share information a

S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)

S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)

S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)

S-8 POS - PRA Health Sciences, Inc. (0001613859) (Filer)

POSASR - PRA Health Sciences, Inc. (0001613859) (Filer)

25-NSE - PRA Health Sciences, Inc. (0001613859) (Subject)

8-K - PRA Health Sciences, Inc. (0001613859) (Filer)

8-K - PRA Health Sciences, Inc. (0001613859) (Filer)

8-K - PRA Health Sciences, Inc. (0001613859) (Filer)

8-K - PRA Health Sciences, Inc. (0001613859) (Filer)